Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the 30th Annual ROTH Conference

ORLANDO, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the 30th Annual...
February 27, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the Inaugural LD Micro Virtual Conference

ORLANDO, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the inaugural LD...
February 26, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program

ORLANDO, Fla., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer...
January 31, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs

BANFF, Alberta, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said William Mitchell, MD, PhD*, Professor of Pathology, Microbiology & Immunology at Vanderbilt...
January 29, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the BIO CEO & Investor Conference

ORLANDO, Fla., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO &...
January 26, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection

ORLANDO, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of Pathology,...
January 25, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice chairman for translational...
January 23, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.

ORLANDO, Fla., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today commented on the overall market opportunity for its...
January 17, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility

ORLANDO, Fla., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today said it has entered into a sale and leaseback agreement for...
January 11, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Enhances Manufacturing Efficiency of Ampligen

ORLANDO, Fla., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), has successfully tested a new chemical catalyst used in the manufacturing process of Ampligen®, a...